Across TCGA pan-cancer cohorts, NAP1L4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NAP1L4 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NAP1L4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NAP1L4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, BLCA, and LIHC are the cancer types where NAP1L4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.677	.004	24	view →
BLCA	OS	Median	All	0.185	0.618	.010	18	view →
LIHC	DFS	Median	All	0.020	0.554	<.001	12	view →
UCEC	DFS	Median	All	0.955	0.628	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NAP1L4 tumor-vs-normal RNA expression · all NAP1L4 data types